News | February 17, 2011

Portable Driver Allows First Artificial Heart Patient to Leave a Hospital

February 17, 2011 – On Jan. 15, after 864 days of life with an artificial heart, Charles Okeke received a dual heart and kidney transplant at the Mayo Clinic Hospital in Phoenix. Okeke had been implanted with the Total Artificial Heart, from SynCardia.

Okeke made headlines in May 2010 when he became the first Total Artificial Heart patient in U.S. history to leave the hospital without a human heart. He was able to return home as part of an FDA-approved Investigational Device Exemption (IDE) clinical study of the 13.5-lb Freedom portable driver.

On Sept. 3, 2008, Okeke was implanted with the device after his body rejected his previous donor heart transplant he’d received at age 30. For more than 600 days, Okeke was confined to the hospital by the only FDA-approved driver for powering the artificial heart, the 418-lb “Big Blue”. Due to the previous transplant, Okeke’s body produced antibodies that made it challenging for him to receive a matching donor heart.

In March 2010, SynCardia received approval from the FDA to conduct an IDE clinical study of the first U.S. portable driver designed to power the device both inside and outside the hospital. On May 3, 2010, Okeke was discharged from the Mayo Clinic wearing the driver in a backpack. He returned home and was supported by the driver for 253 days.

This was only the third time in the world that a patient was bridged to a dual heart and kidney transplant with the Total Artificial Heart.

For more information: www.syncardia.com

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
Overlay Init